We are LifeScience and Healthcare focussed venture capital firm.Read More
We invest in innovative private early- to mid-stage human Life Science companies that address important medical needs with novel technologies or products backed by compelling science and with differentiated advantages over current treatment options.
We mostly invest in drug development and, to a lesser degree, in diagnostics and medical technology.
The amount we aim to invest over the life time of our portfolio companies is up to CHF USD 50 Million. BioMedPartners often plays the lead or co-lead investor role structuring the transaction and syndicating with other venture capital firms.
Our focus is on the highly specialized Life Science market, a market we understand due to our team’s decades of expertise in the field. Within this focused approach, we diversify over diseases, geographies and stages of company development to limit risk.
We believe companies can truly make a difference if their products differentiate themselves from their competitors. We do not invest in me-too-products; instead we actively look for companies which develop next-generation medicines with a unique selling point that puts them ahead of competition.
In our experience a management team with the right characteristics consistently outperforms the market. To that end we look for outstanding and ambitious management teams with a good track record.
We only invest in those companies that are actively looking to expand their business in terms of in- or out-licensing opportunities around their pipeline. These efforts do not only drive growth, they also reduce the company’s exposure to risk.
Information technology advances will affect all areas of pre-clinical and clinical trials, including patient recruitment and selection, data capture, data analysis and post market surveillance. Adverse event detection, reporting and analysis will also be impacted. Superior outcomes characterization will yield more effective treatment protocols and clinical pathways.Our specific areas of interest include:
Pharmaceutical services and outsourcing
Private-pay components of healthcare services (dental & medical)
Long-term care in private pay market
Consumer-driven health plans